Literature DB >> 31005059

Mu opioid receptors in the medial habenula contribute to naloxone aversion.

L J Boulos1,2,3,4,5, S Ben Hamida1,2,3,4,5, J Bailly1, M Maitra1, A T Ehrlich1,2,3,4,5, C Gavériaux-Ruff2,3,4,5, E Darcq1, B L Kieffer6,7,8,9,10.   

Abstract

The medial habenula (MHb) is considered a brain center regulating aversive states. The mu opioid receptor (MOR) has been traditionally studied at the level of nociceptive and mesolimbic circuits, for key roles in pain relief and reward processing. MOR is also densely expressed in MHb, however, MOR function at this brain site is virtually unknown. Here we tested the hypothesis that MOR in the MHb (MHb-MOR) also regulates aversion processing. We used chnrb4-Cre driver mice to delete the Oprm1 gene in chnrb4-neurons, predominantly expressed in the MHb. Conditional mutant (B4MOR) mice showed habenula-specific reduction of MOR expression, restricted to chnrb4-neurons (50% MHb-MORs). We tested B4MOR mice in behavioral assays to evaluate effects of MOR activation by morphine, and MOR blockade by naloxone. Locomotor, analgesic, rewarding, and motivational effects of morphine were preserved in conditional mutants. In contrast, conditioned place aversion (CPA) elicited by naloxone was reduced in both naïve (high dose) and morphine-dependent (low dose) B4MOR mice. Further, physical signs of withdrawal precipitated by either MOR (naloxone) or nicotinic receptor (mecamylamine) blockade were attenuated. These data suggest that MORs expressed in MHb B4-neurons contribute to aversive effects of naloxone, including negative effect and aversive effects of opioid withdrawal. MORs are inhibitory receptors, therefore we propose that endogenous MOR signaling normally inhibits chnrb4-neurons of the MHb and moderates their known aversive activity, which is unmasked upon receptor blockade. Thus, in addition to facilitating reward at several brain sites, tonic MOR activity may also limit aversion within the MHb circuitry.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31005059      PMCID: PMC6901535          DOI: 10.1038/s41386-019-0395-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  65 in total

1.  Habenular signaling in nicotine reinforcement.

Authors:  Christie D Fowler; Paul J Kenny
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

Review 2.  Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability.

Authors:  Christie D Fowler; Paul J Kenny
Journal:  Neuropharmacology       Date:  2013-09-18       Impact factor: 5.250

Review 3.  The medial habenula and interpeduncular nucleus circuitry is critical in addiction, anxiety, and mood regulation.

Authors:  Ian McLaughlin; John A Dani; Mariella De Biasi
Journal:  J Neurochem       Date:  2017-08       Impact factor: 5.372

Review 4.  Translating the Habenula-From Rodents to Humans.

Authors:  Laura-Joy Boulos; Emmanuel Darcq; Brigitte Lina Kieffer
Journal:  Biol Psychiatry       Date:  2016-06-07       Impact factor: 13.382

5.  Differential expression and function of nicotinic acetylcholine receptors in subdivisions of medial habenula.

Authors:  Pei-Yu Shih; Staci E Engle; Gyeon Oh; Purnima Deshpande; Nyssa L Puskar; Henry A Lester; Ryan M Drenan
Journal:  J Neurosci       Date:  2014-07-16       Impact factor: 6.167

6.  Habenular CB1 Receptors Control the Expression of Aversive Memories.

Authors:  Edgar Soria-Gómez; Arnau Busquets-Garcia; Fei Hu; Amine Mehidi; Astrid Cannich; Liza Roux; Ines Louit; Lucille Alonso; Theresa Wiesner; Francois Georges; Danièle Verrier; Peggy Vincent; Guillaume Ferreira; Minmin Luo; Giovanni Marsicano
Journal:  Neuron       Date:  2015-09-24       Impact factor: 17.173

7.  Phylogeny and ontogeny of the habenular structure.

Authors:  Hidenori Aizawa; Ryunosuke Amo; Hitoshi Okamoto
Journal:  Front Neurosci       Date:  2011-12-21       Impact factor: 4.677

8.  Habenula circuit development: past, present, and future.

Authors:  Carlo A Beretta; Nicolas Dross; Jose A Guiterrez-Triana; Soojin Ryu; Matthias Carl
Journal:  Front Neurosci       Date:  2012-04-23       Impact factor: 4.677

9.  Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal.

Authors:  Rubing Zhao-Shea; Steven R DeGroot; Liwang Liu; Markus Vallaster; Xueyan Pang; Qin Su; Guangping Gao; Oliver J Rando; Gilles E Martin; Olivier George; Paul D Gardner; Andrew R Tapper
Journal:  Nat Commun       Date:  2015-04-21       Impact factor: 14.919

10.  Habenular expression of rare missense variants of the β4 nicotinic receptor subunit alters nicotine consumption.

Authors:  Marta A Slimak; Jessica L Ables; Silke Frahm; Beatriz Antolin-Fontes; Julio Santos-Torres; Milena Moretti; Cecilia Gotti; Inés Ibañez-Tallon
Journal:  Front Hum Neurosci       Date:  2014-01-27       Impact factor: 3.169

View more
  15 in total

1.  Mu-Opioid Receptors Expressed in Glutamatergic Neurons are Essential for Morphine Withdrawal.

Authors:  Xin-Yan Zhang; Qing Li; Ye Dong; Wei Yan; Kun Song; Yong-Qin Lin; Yan-Gang Sun
Journal:  Neurosci Bull       Date:  2020-05-25       Impact factor: 5.203

2.  Mu opioid receptors on hippocampal GABAergic interneurons are critical for the antidepressant effects of tianeptine.

Authors:  Jaena Han; Valentine Andreu; Cory Langreck; Elizabeth A Pekarskaya; Steven G Grinnell; Florence Allain; Valerie Magalong; John Pintar; Brigitte L Kieffer; Alexander Z Harris; Jonathan A Javitch; René Hen; Katherine M Nautiyal
Journal:  Neuropsychopharmacology       Date:  2021-09-30       Impact factor: 8.294

3.  The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.

Authors:  Julien C Dodu; Rebecca K Moncayo; M Imad Damaj; Joel E Schlosburg; Hamid I Akbarali; Lesley D O'Brien; Debra A Kendall; Zhixing Wu; Dai Lu; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2021-10-08       Impact factor: 4.402

4.  Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents.

Authors:  Matthew E Klein; Joshua Chandra; Salma Sheriff; Roberto Malinow
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-15       Impact factor: 11.205

Review 5.  The Negative Affect of Protracted Opioid Abstinence: Progress and Perspectives From Rodent Models.

Authors:  Lola Welsch; Julie Bailly; Emmanuel Darcq; Brigitte Lina Kieffer
Journal:  Biol Psychiatry       Date:  2019-08-06       Impact factor: 13.382

6.  Endogenous µ-opioid receptor activity in the lateral and capsular subdivisions of the right central nucleus of the amygdala prevents chronic postoperative pain.

Authors:  Andrew H Cooper; Naomi S Hedden; Gregory Corder; Sydney R Lamerand; Renee R Donahue; Julio C Morales-Medina; Lindsay Selan; Pranav Prasoon; Bradley K Taylor
Journal:  J Neurosci Res       Date:  2021-05-06       Impact factor: 4.164

7.  T-Type Calcium Channels Contribute to Burst Firing in a Subpopulation of Medial Habenula Neurons.

Authors:  Casey R Vickstrom; Xiaojie Liu; Yuqi Zhang; Lianwei Mu; Thomas J Kelly; Xudong Yan; Meng-Ming Hu; Shana T Snarrenberg; Qing-Song Liu
Journal:  eNeuro       Date:  2020-08-12

8.  Habenula kisspeptin retrieves morphine impaired fear memory in zebrafish.

Authors:  Mageswary Sivalingam; Satoshi Ogawa; Ishwar S Parhar
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

Review 9.  The transition to compulsion in addiction.

Authors:  Christian Lüscher; Trevor W Robbins; Barry J Everitt
Journal:  Nat Rev Neurosci       Date:  2020-03-30       Impact factor: 34.870

10.  μ-Opioid Receptors on Distinct Neuronal Populations Mediate Different Aspects of Opioid Reward-Related Behaviors.

Authors:  Amie L Severino; Nitish Mittal; Joshua K Hakimian; Nathanial Velarde; Ani Minasyan; Ralph Albert; Carlos Torres; Nicole Romaneschi; Camille Johnston; Suchi Tiwari; Alex S Lee; Anna M Taylor; Claire Gavériaux-Ruff; Brigitte L Kieffer; Christopher J Evans; Catherine M Cahill; Wendy M Walwyn
Journal:  eNeuro       Date:  2020-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.